Gilead Sciences (NASDAQ:GILD) received a $80.00 price target from research analysts at Credit Suisse Group in a note issued to investors on Wednesday. The brokerage presently has a “hold” rating on the biopharmaceutical company’s stock. Credit Suisse Group’s target price suggests a potential upside of 8.20% from the stock’s current price.
Other analysts also recently issued research reports about the stock. BMO Capital Markets reaffirmed a “hold” rating on shares of Gilead Sciences in a report on Wednesday. Leerink Swann upped their price target on shares of Gilead Sciences from $84.00 to $85.00 and gave the company a “market perform” rating in a report on Thursday, October 19th. TheStreet raised shares of Gilead Sciences from a “c+” rating to a “b-” rating in a report on Thursday, September 7th. Berenberg Bank reaffirmed a “buy” rating and issued a $96.00 price target (up previously from $86.00) on shares of Gilead Sciences in a report on Wednesday, September 6th. Finally, Maxim Group reissued a “hold” rating on shares of Gilead Sciences in a research note on Thursday, October 19th. One research analyst has rated the stock with a sell rating, fourteen have assigned a hold rating, sixteen have assigned a buy rating and one has given a strong buy rating to the stock. Gilead Sciences presently has a consensus rating of “Buy” and a consensus target price of $85.03.
Shares of Gilead Sciences (NASDAQ:GILD) traded up $0.04 during midday trading on Wednesday, hitting $73.94. 4,380,000 shares of the company’s stock traded hands, compared to its average volume of 7,400,000. Gilead Sciences has a 12 month low of $63.76 and a 12 month high of $86.27. The stock has a market capitalization of $96,570.00, a P/E ratio of 8.41, a PEG ratio of -1.59 and a beta of 1.13. The company has a quick ratio of 3.56, a current ratio of 3.68 and a debt-to-equity ratio of 1.10.
Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings results on Thursday, October 26th. The biopharmaceutical company reported $2.27 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.13 by $0.14. Gilead Sciences had a net margin of 42.22% and a return on equity of 57.15%. The company had revenue of $6.51 billion for the quarter, compared to the consensus estimate of $6.40 billion. During the same quarter in the prior year, the firm earned $2.75 earnings per share. The company’s revenue for the quarter was down 13.2% compared to the same quarter last year. equities research analysts expect that Gilead Sciences will post 8.53 earnings per share for the current fiscal year.
In related news, EVP Gregg H. Alton sold 15,000 shares of the company’s stock in a transaction that occurred on Wednesday, November 1st. The shares were sold at an average price of $74.82, for a total transaction of $1,122,300.00. Following the completion of the transaction, the executive vice president now owns 77,363 shares of the company’s stock, valued at $5,788,299.66. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider John F. Milligan sold 220,000 shares of the stock in a transaction on Monday, November 13th. The stock was sold at an average price of $72.88, for a total transaction of $16,033,600.00. The disclosure for this sale can be found here. Insiders have sold 461,666 shares of company stock valued at $34,072,567 in the last ninety days. 1.30% of the stock is currently owned by company insiders.
Several institutional investors have recently added to or reduced their stakes in the company. Welch Investments LLC acquired a new stake in Gilead Sciences during the 3rd quarter valued at $108,000. Wealthcare Advisory Partners LLC acquired a new stake in Gilead Sciences during the 3rd quarter valued at $133,000. Horan Capital Advisors LLC. acquired a new stake in Gilead Sciences during the 3rd quarter valued at $144,000. Migdal Insurance & Financial Holdings Ltd. acquired a new stake in Gilead Sciences during the 2nd quarter valued at $147,000. Finally, Hanson & Doremus Investment Management grew its holdings in Gilead Sciences by 806.5% during the 3rd quarter. Hanson & Doremus Investment Management now owns 1,813 shares of the biopharmaceutical company’s stock valued at $147,000 after purchasing an additional 1,613 shares in the last quarter. 75.94% of the stock is owned by institutional investors.
WARNING: “Gilead Sciences (GILD) PT Set at $80.00 by Credit Suisse Group” was first posted by Transcript Daily and is owned by of Transcript Daily. If you are accessing this piece on another site, it was copied illegally and republished in violation of US and international copyright and trademark laws. The legal version of this piece can be accessed at https://transcriptdaily.com/2018/01/05/gilead-sciences-gild-pt-set-at-80-00-by-credit-suisse-group.html.
About Gilead Sciences
Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.